Proliferative Diabetic Retinopathy (PDR) Market Size Forecasted To Achieve $4.02 Billion By 2029 With Steady Growth

The Proliferative Diabetic Retinopathy (PDR) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Proliferative Diabetic Retinopathy (PDR) Market Size and Projected Growth Rate?
Recent years have witnessed a significant expansion in the market size of Proliferative Diabetic Retinopathy (PDR). The market, presently valued at $2.42 billion in 2024, is predicted to escalate up to $2.7 billion in 2025, showcasing a compound annual growth rate (CAGR) of 11.6%. Elements contributing to the growth in the preceding period include increased incidence of diabetes, shifts in lifestyle and consumption of unhealthy foods, initiatives launched by the government, and a surge in vision loss related to diabetes.

The market size for proliferative diabetic retinopathy (PDR) is projected to witness substantial growth in the coming years, with an anticipated worth of $4.02 billion by 2029, representing a compound annual growth rate (CAGR) of 10.5%. The reasons for this significant growth during the predicted phase may be attributed to the increase in aging population, heightened public consciousness and knowledge about diabetes, funds allocated for research and development, and the growing need for combination therapies. The forecast period will see some leading trends including enhanced diagnostic technologies, breakthroughs in therapy options, incorporation of artificial intelligence (AI) for early detection, advancements in gene therapy, and high-tech retinal imaging.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12911

What Are the Major Segments in the Proliferative Diabetic Retinopathy (PDR) Market?
The proliferative diabetic retinopathy (PDR) market covered in this report is segmented -

1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy, Intraocular Steroids, Laser Surgery, Vitrectomy
2) By Mode of Administration: Injectables, Oral, Other Mode Of Administrations
3) By Application: Hospitals, Clinics, Other Applications

Subsegments:
1) By Anti-VEGF Therapy: Aflibercept, Ranibizumab, Bevacizumab
2) By Intraocular Steroids: Triamcinolone Acetonide, Dexamethasone Implant, Fluocinolone Acetonide
3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Laser Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy, Anterior Vitrectomy

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp

What Are The Driving Proliferative Diabetic Retinopathy (PDR) Market Evolution?
The upward trajectory of diabetes cases is predicted to catalyze the proliferative diabetic retinopathy (PDR) market's advancement. Diabetes, a long-term medical condition, is defined by high glucose levels in the bloodstream and is the primary contributor to proliferative diabetic retinopathy disease. This disease can be managed by various measures to prevent further retinal damage and maintain vision. For example, the National Health Service (NHS), a UK government department, reported in June 2024 that the number of individuals under 40 with diabetes rose from 173,166 in 2022 to 216,440 in 2023. This substantial uptrend underscores a worrisome pattern among this demographic. The data paints a picture of a swift surge in diabetes among the younger generations, which fuels the proliferative diabetic retinopathy (PDR) market. A similar growth-driving factor in the proliferative diabetic retinopathy (PDR) market is the escalating incidence of obesity. Obesity is a multifactorial, chronic illness that results in excessive body fat and, occasionally, degraded health. Obesity is associated with insulin resistance, persistent low-intensity inflammation, and heightened oxidative stress, which can harm the retinal microvessels and facilitate the onset of diabetic retinopathy. For example, according to a 2022 report by Trust for America's Health, a non-profit organization in the USA, obesity rates continue to surge, with 40% of American adults being obese. This indicates a climb from the previous year, with 19 states showing adult obesity rates exceeding 35%, a rise from 16 states the previous year. Thus, the escalating incidence of obesity propels the growth of the proliferative diabetic retinopathy (PDR) market.

Which Firms Dominate The Proliferative Diabetic Retinopathy (PDR) Market Segments?
Major companies operating in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

What Trends Are Expected to Dominate the Proliferative Diabetic Retinopathy (PDR) Market in the Next 5 Years?
Leading corporations in the proliferative diabetic retinopathy market are consistently concentrated on innovating new therapies to improve treatment effectiveness, lessen treatment complications, and boost patient results. For instance, in June 2022, Biogen - a biotechnology firm from the US, and Samsung Bioepis - a biotechnology organization from South Korea, launched Byooviz (ranibizumab-nuna), the inaugural ophthalmology biosimilar in the US. These products are deployed for the treatment of individuals suffering from diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

Which Is The Largest Region In The Proliferative Diabetic Retinopathy (PDR) Market?
North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Proliferative Diabetic Retinopathy (PDR) Market?
2. What is the CAGR expected in the Proliferative Diabetic Retinopathy (PDR) Market?
3. What Are the Key Innovations Transforming the Proliferative Diabetic Retinopathy (PDR) Industry?
4. Which Region Is Leading the Proliferative Diabetic Retinopathy (PDR) Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.